Brought to you by 
Exscientia inks strategic drug discovery collaboration with GSK
18 Jun 2020
Executive Summary
Exscientia Ltd. entered into a drug discovery collaboration with GlaxoSmithKline PLC in which it agreed to apply its AI platform to discover novel selective small molecules with GSK for up to 10 disease-related targets.
Deal Industry
- Digital Health
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Exscientia inks strategic drug discovery collaboration with GSK
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice